Crossmark

Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort

Crossref DOI link: https://doi.org/10.1186/s12885-019-5345-6

Published Online: 2019-02-12

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Eriksen, Ann C. https://orcid.org/0000-0002-3905-4132
Sørensen, Flemming B.

Lindebjerg, Jan

Hager, Henrik

dePont Christensen, René

Kjær-Frifeldt, Sanne

Hansen, Torben F.
Funding

Funding for this research was provided by:

The research Council of Lillebaelt Hospital (100.000 DKK)

Dansk Kræftforsknings Fond (127.000 DKK)
License Information

Text and Data Mining valid from 2019-02-12
More Information

Article History

Received: 19 April 2018

Accepted: 1 February 2019

First Online: 12 February 2019

Ethics approval and consent to participate

: The Regional Committees on Health Research Ethics for Southern Denmark approved the study and exempted the study from the rule of informed consent in their approvel (S-20140119). The study was also approved by the Danish Data Protection Agency (14/26345). All patients were screened in the Danish Registry of Tissue Utilization before enrollment in the study.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.